Endogenous Metabolite-Activated G Protein-Coupled Receptors in Cardiovascular Disease: Mechanisms, Evidence Appraisal, and Potential Drug Target Identification

Background: G protein-coupled receptors (GPCRs) can recognize endogenous small-molecule metabolites and are important regulators of cardiovascular diseases associated with metabolic disorders; however, their comprehensive classification and translational value remain to be clarified. Methods: This narrative review synthesizes recent research findings on endogenous metabolite-activated GPCRs, summarizes ligand-receptor pairings for the various GPCR classes, analyzes downstream signaling pathways and the regulatory mechanisms underlying cardiovascular pathology, and evaluates the evidence supporting these receptors as potential drug targets. Only studies addressing endogenous metabolite-GPCR interactions were included; exogenous drugs and synthetic ligands were excluded unless used as pharmacological tools. Results: Metabolites such as short-chain fatty acids, ceramides, bile acids, and succinate interact with their respective GPCRs and are involved in cardiovascular pathophysiology, including blood pressure regulation, atherosclerosis, myocardial injury, and aortic dissection. Some of these metabolites can serve as diagnostic biomarkers, and intervention strategies targeting this axis hold therapeutic potential. Through structured appraisal of evidence strength, druggability, and tissue-specific expression, we identify SUCNR1 (GPR91), GPBAR1 (TGR5), and the ceramide receptor complex CYSLTR2/P2RY6 as high-priority candidates for drug development, with GPR35, LPAR subtypes, and hydroxycarboxylic acid receptor 2 (HCAR2, also known as HCA2/GPR109A) considered moderate-priority candidates. Conclusions: The metabolite-GPCR axis links metabolism and cardiovascular disease, providing new targets and approaches for its diagnosis and treatment.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Discovery and Pharmacology
Published
2026-11-17
DOI
https://doi.org/10.53941/ijddp.2026.100026
Primary Topic
Receptor Mechanisms and Signaling
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Endogenous Metabolite-Activated G Protein-Coupled Receptors in Cardiovascular Disease: Mechanisms, Evidence Appraisal, and Potential Drug Target Identification

Zequn Yin, Weijie Yan, Yajun Duan, 志伟 赵 et al.
1 links
International Journal of Drug Discovery and Pharmacology
Receptor Mechanisms and Signaling
article

Endogenous Metabolite-Activated G Protein-Coupled Receptors in Cardiovascular Disease: Mechanisms, Evidence Appraisal, and Potential Drug Target Identification

Zequn Yin, Weijie Yan, Yajun Duan, 志伟 赵, Zhenxiao Ma, Shihao Fu, Nan Li, Yanxiang Wang
article en

Abstract

Background: G protein-coupled receptors (GPCRs) can recognize endogenous small-molecule metabolites and are important regulators of cardiovascular diseases associated with metabolic disorders; however, their comprehensive classification and translational value remain to be clarified. Methods: This narrative review synthesizes recent research findings on endogenous metabolite-activated GPCRs, summarizes ligand-receptor pairings for the various GPCR classes, analyzes downstream signaling pathways and the regulatory mechanisms underlying cardiovascular pathology, and evaluates the evidence supporting these receptors as potential drug targets. Only studies addressing endogenous metabolite-GPCR interactions were included; exogenous drugs and synthetic ligands were excluded unless used as pharmacological tools. Results: Metabolites such as short-chain fatty acids, ceramides, bile acids, and succinate interact with their respective GPCRs and are involved in cardiovascular pathophysiology, including blood pressure regulation, atherosclerosis, myocardial injury, and aortic dissection. Some of these metabolites can serve as diagnostic biomarkers, and intervention strategies targeting this axis hold therapeutic potential. Through structured appraisal of evidence strength, druggability, and tissue-specific expression, we identify SUCNR1 (GPR91), GPBAR1 (TGR5), and the ceramide receptor complex CYSLTR2/P2RY6 as high-priority candidates for drug development, with GPR35, LPAR subtypes, and hydroxycarboxylic acid receptor 2 (HCAR2, also known as HCA2/GPR109A) considered moderate-priority candidates. Conclusions: The metabolite-GPCR axis links metabolism and cardiovascular disease, providing new targets and approaches for its diagnosis and treatment.

International Journal of Drug Discovery and PharmacologyVol. 5(4)
University of Science and Technology of China (CN)
Good health and well-being
Receptor Mechanisms and Signaling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon